United Therapeutics (UTHR) Retained Earnings (2009 - 2026)

United Therapeutics has disclosed Retained Earnings across 18 years of filings, most recently posting $9.2 billion for Q2 2026.

• In Q2 2026, Retained Earnings rose 16.69% year-over-year to $9.2 billion; the TTM figure through Jun 2026 stood at $9.2 billion (up 16.69% YoY), while the FY2025 annual figure was $8.6 billion, up 18.48% from the prior year.
• Retained Earnings came in at $9.2 billion for Q2 2026 at United Therapeutics, up from $8.8 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $9.2 billion in Q2 2026 to a low of $4.6 billion in Q1 2022.
• Average Retained Earnings over 5 years is $6.6 billion, with a median of $6.5 billion recorded in 2024.
• Year-over-year, Retained Earnings advanced 15.61% in 2022 and rose 19.88% in 2024.
• Over 5 years, Retained Earnings stood at $5.0 billion in 2022, then advanced by 19.53% to $6.0 billion in 2023, then climbed by 19.83% to $7.2 billion in 2024, then gained by 18.48% to $8.6 billion in 2025, then rose by 7.1% to $9.2 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $9.2 billion in Q2 2026, $8.8 billion in Q1 2026, and $8.6 billion in Q4 2025.